鬱病に対する実践主導の品質改善の費用対効果:ランダム化制御試験の結果
M Schoenbaum1, J Unützer, C Sherbourne
1RAND, 1200 S Hayes St, Arlington, VA 22202, USA. mikels@rand.org
JAMA
|September 19, 2001
まとめ
プライマリケアにおけるうつ病に対する品質改善の介入は,受け入れられた医療治療法と比較できる社会的費用対効果を示した. これらの介入は,患者の雇用結果を改善した.
科学分野:
- 医療サービス 研究 医療サービス
- 臨床心理学の臨床心理学について
- 公衆衛生は公衆衛生である.
背景:
- 鬱病は,障害の重要な世界的な原因です.
- プライマリケア施設での低い治療率は,障害者負担に寄与しています.
- 鬱病の治療を改善するために,効果的な介入が必要である.
研究 の 目的:
- プライマリケアにおけるうつ病治療における2つの品質改善 (QI) 介入の社会的費用対効果を評価する.
- QIの介入が患者の雇用状況に与える影響を評価する.
主な方法:
- グループレベルのランダム化比較試験は46のプライマリケアクリニックで実施されました.
- うつ病スクリーニングの結果が陽性だった1356人の患者が対象となった.
- 2つのQI介入 (QI-medsとQI-therapy) は,24ヶ月間にわたる通常のケアと比較されました.
主要な成果:
- 両方のQI介入は,既定の医療治療に匹敵する費用対効果を示し,獲得したQALYあたりのコストは許容範囲内であった.
- QI療法を受けた患者は,うつ病の負担を伴う日数が著しく減り,雇用された日数が増加しました.
- QI-medsはまた,うつ病の負担を軽減し,雇用日数を増加させる傾向を示しました.
結論:
- 鬱病に対する実践による品質改善の取り組みは,社会的に費用対効果が高くなります.
- これらの介入は,患者の雇用に肯定的な影響を及ぼし,雇用者と他の利害関係者に利益をもたらします.
- QI介入は,プライマリケアにおけるうつ病管理を改善するための実行可能な戦略です.
関連する概念動画
01:05Long-term Depression
27.3K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
27.3K
01:54The Placebo Effect
5.9K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
5.9K
02:07Blind Procedures
10.8K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.8K
01:18Depression: Overview
1.2K
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
1.2K
01:23Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
01:30Electroconvulsive Therapy
2.6K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.6K